SOURCE: Paragon Financial Limited

Paragon Financial Limited

February 23, 2012 08:20 ET

Investor Optimism in Biotech Skyrockets - Cardium Therapeutics and Oncothyreon on the Upswing

The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon

NEW YORK, NY--(Marketwire - Feb 23, 2012) - Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data company OnBioVC, biotech companies attracted close to double the amount of investment in the fourth quarter of 2011 than they did in the same period of 2010. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cardium Therapeutics Inc. (NYSE Amex: CXM) & Oncothyreon, Inc. (NASDAQ: ONTY). Access to the full company reports can be found at:

www.paragonreport.com/CXM

www.paragonreport.com/ONTY

According to BIO Industry Analysis survey data, there is renewed optimism surrounding the biotechnology industry among investors amid signs that FDA approvals may be on the rise in 2012. "The BIO CEO & Investor Conference synthesized the overall mood within the industry of momentum and progress with recent approvals and increased M&A activity, and optimism for the year ahead," said Alan Eisenberg, executive vice president of Emerging Companies and Business Development at BIO.

The BIO survey shows that 56 percent of investors think now is a good time to invest -- specifically with early stage companies and those focused on autoimmune disease and oncology.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Biotech stocks have been on an impressive upswing this year, handedly outperforming the broader market. The SPDR S&P Biotech ETF (XBI) -- which holds an equal amount of large companies as well as small companies, translating to increased risks and potentially higher rewards -- is up more than 15 percent year to date.

Cardium Therapeutics' current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. In late January, Cardium reported on new insights and confirmatory preclinical study results on the Generx (Ad5FGF-4) angiogenic therapy product candidate based on the Company's sponsored research conducted at Emory University.

Oncothyreon's primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. Shares of Oncothyreon have been on a tear this year -- gaining more than 17 percent.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer.